FDA Determines Regulatory Review Period for ABILIFY Patent Extension

Summary

The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for the patent extension of ABILIFY, a human drug product, following a submission to the Director of Patents and Trademarks at the US Department of Commerce.